FIGURE 6.
Progression-free survival in the group of patients treated with bevacizumab, in β-blockers users (----) compared with non-β-blockers users (___) (10.1 vs 8.66 months, HR: 1.35, 95% CI: 0.68–2.53, P = 0.40).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.